Literature DB >> 15602366

[Reversible postpartum cerebral angiopathy associated with bromocriptine therapy].

B Barroso1, P Bigou, K Martin, A Lippa, L Chabouni, A Dakar, E Larribau, J-M Larrieu.   

Abstract

BACKGROUND: Postpartum is known to be an important risk factor for stroke. Bromocriptine may induce cerebral angiopathy. CASE DESCRIPTION: We report the case of a 26-year-old postpartum woman who presented with headaches, seizures, hypertension and acute renal failure eight days after the beginning of a treatment with bromocriptine prescribed for lactation suppression. Brain MRI and MR angiogram excluded cortical vein thrombosis and revealed multiple abnormal areas of increased signal in the cortex with segmental arterial narrowings of intracranial vasculitis. The patient completely recovered within one week after drug withdrawal. Biological and radiological abnormalities were also reversible. Following the chronology bromocriptine was most likely responsible for this adverse cerebral and systemic event.
CONCLUSION: Clinicians should be aware of bromocripine-related postpartum cerebral angiopathy, a rarely described but serious complication of bromocriptine used to prevent postpartum breast engorgement.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15602366     DOI: 10.1016/s0035-3787(04)71165-0

Source DB:  PubMed          Journal:  Rev Neurol (Paris)        ISSN: 0035-3787            Impact factor:   2.607


  3 in total

1.  Benign cerebral angiopathy; postpartum cerebral angiopathy: characteristics and treatment.

Authors:  Sofia Calado; Miguel Viana-Baptista
Journal:  Curr Treat Options Cardiovasc Med       Date:  2006-05

2.  Management of pituitary adenoma with mass effect in pregnancy: a case report.

Authors:  U V Okafor; I O Onwuekwe; H U Ezegwui
Journal:  Cases J       Date:  2009-09-08

3.  Management of pituitary adenoma with mass effect in pregnancy: a case report.

Authors:  Uv Okafor; Io Onwuekwe; Hu Ezegwui
Journal:  Cases J       Date:  2009-11-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.